# Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Source: https://onco.cc/trials/nct05332561/  
OnCo record `nct05332561` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This German study assigns additional treatment after surgery according to tumour profiling. Its olaparib arm can accept qualifying tumour-only BRCA alterations.

## Summary

The registry lists NCT05332561 as recruiting, last updated 2025-03-20. Enrolment is 240 planned participants, an estimate. Interventions: Atezolizumab 1200 mg in 20 ML Injection, Inavolisib, Ipatasertib, Olaparib, Sacituzumab govitecan, Trastuzumab/pertuzumab. Primary measures include Invasive Disease-free Survival (IDFS) as defined by Hudis et al in the entire study population four years after surgery. No results are posted in the registry; this does not exclude separate publications. The current registry lists German sites and no US site. Arm 4 accepts inactivating somatic or germline BRCA1/2, including homozygous deletions, or inactivating germline PALB2, with assignment exclusively determined by the molecular tumour board. Separate arms target separate pathways; the platform is not a combined PARP regimen or proof of adjuvant benefit for somatic-only BRCA.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-10
- Registry id: NCT05332561
- Phase: 2
- Setting: Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer - a Multicenter, Open-label, Umbrella Phase-II Study - COGNITION-GUIDE
- Sponsor: German Cancer Research Center

## Sources

- ClinicalTrials.gov NCT05332561: https://clinicaltrials.gov/study/NCT05332561

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/)

---
JSON: https://onco.cc/api/v1/entities/nct05332561.json